Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the region of Madrid, Spain, 2008–2011

Eurosurveillance

Volumn 19, Issue 40, 2014, Pages

  Gutierrez Rodriguez M A ^a   Ordobas Gavin M A ^a   Garcia Comas L ^a   Sanz Moreno, J C ^a   CoRdoba Deorador E ^a   Lasheras Carbajo, M D ^a   Taveira Jimenez J A ^a   Martin Martinez F ^a   Iniesta Fornies, D ^a   Arce Arnaez, A ^a  

^a Comunidad de Madrid ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; VACCINE;

ADULT; AGED; ARTICLE; BACTEREMIA; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SURVEILLANCE; EMPYEMA; FEMALE; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTION; PNEUMONIA; QUESTIONNAIRE; SEROTYPE; SPAIN; VACCINATION; CLASSIFICATION; HEALTH SURVEY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS; RISK; SEASON; SEX RATIO; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; RISK; SEASONS; SEX DISTRIBUTION; SPAIN; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 84908046780     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.40.20922     Document Type: Article

References (41)

1. Pneumococcal vaccines, WHO position paper - 2012. Weekly epidemiological record. 2012;87(14):129-44.
2. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Weekly epidemiological record. 2008; 83(42):373-84.
3. Musher DM. Streptococcus pneumoniae. In: Mandell, Douglas, Bennett, editors. Enfermedades infecciosas. Principios y práctica. 2nd ed. Elsevier España SA:Madrid; 2006.
4. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
5. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48-58. http://dx.doi.org/10.1503/cmaj.080734
6. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-7.
7. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-46. http://dx.doi.org/10.1056/NEJMoa022823
8. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760-8. http://dx.doi.org/10.1016/S1473-3099(11)70090-1
9. Vacuna de neumococo. Vacunación en adultos. Recomendaciones. Madrid: Subdirección General de Promoción de la Salud y Epidemiología: Ministerio de Sanidad y Consumo; 2004. [Accessed June 2013]. Available from: http://www.msssi.gob.es/ciudadanos/proteccionSalud/vacunaciones/docs/ recoVacunasAdultos.pdf
10. Estadística de Población de la Comunidad de Madrid. Características demográficas básicas. [Accessed June 2013]. Available from: http://www.madrid.org/iestadis/fijas/estructu/demograficas/padron/estructupcrd.htm
11. Orestein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63(6):1055-68.
12. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22:742-6. http://dx.doi.org/10.1093/ije/22.4.742
13. Broome CV, Facklam RR, and Fraser DW. Pneumocococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980;303(10):549-52. http://dx.doi.org/10.1056/NEJM198009043031003
14. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41. http://dx.doi.org/10.1086/648593
15. Active Bacterial Core Surveillance Report (ABCs), Emerging Infections Program Network. Streptococcus pneumoniae, 2011. Atlanta: Centre for Disease Control and Prevention (CDC); 2013. [Accessed June 2013]. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu11.pdf
16. Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30(26):3944-50. http://dx.doi.org/10.1016/j.vaccine.2012.03.060
17. European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive pneumococcal disease in Europe, 2010. Stockholm: ECDC; 2012. [Accessed June 2013]. Available from: http://www.ecdc.europa.eu/en/publications/Publications/invasive-pneumoccocal-disease-surveillance-2010.pdf
18. Hanquet G, Perrocheau A, Kissling E, Bruhl DL, Tarragó D, Stuart J et al. Surveillance of invasive pneumococcal disease in 30 EU countries: towards a European system? Vaccine. 2010;28(23):3920-8. http://dx.doi.org/10.1016/j.vaccine.2010.03.069
19. Guevara M, Barricarte A, Gil-Setas A, Garcia-Irure JJ, Beristain X, Torroba L et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15(11):1013-9. http://dx.doi.org/10.1111/j.1469-0691.2009.02904.x
20. Ardanuy C, Tubau F, Pallares R, Calatayud L, Domínguez MA, Rolo D et al.. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48(1):57-64. http://dx.doi.org/10.1086/594125
21. Ochoa-Gondar O, Vila-Corcoles A. Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002-2009: an increase in serotypes not contained in the heptavalent conjugate vaccine. J Infect. 2011;63(6):434-40. http://dx.doi.org/10.1016/j.jinf.2011.08.013
22. Mu-oz-Almagro C, Ciruela P, Esteva C, Marco F, Navarro M, Bartolome R et al. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 2011;63(2):151-62. http://dx.doi.org/10.1016/j.jinf.2011.06.002
23. Andrews NJ, Waight PA, George RC, Slack ME, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802-8. http://dx.doi.org/10.1016/j.vaccine.2012.09.019
24. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine. 2004;23(2):132-8. http://dx.doi.org/10.1016/j.vaccine.2004.06.016
25. Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis. 2008;8:53. http://dx.doi.org/10.1186/1471-2334-8-53
26. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis. 2005; 40(9):1250-7. http://dx.doi.org/10.1086/429236
27. Vila-Corcoles A, Ochoa-Gondar O, Rodríguez-Blanco T, Gutiérrez-Pérez A, Vila-Rovira A, Group ES. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: A matched case-control study. Hum Vaccin Immunother. 2012;8(5):639-44. http://dx.doi.org/10.4161/hv.19466
28. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962-73. http://dx.doi.org/10.1016/S0140-6736(10)62225-8
29. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec. 2010;85(43):434-6.
30. Hatton P. The use of screening technique as a method of rapidly estimating vaccine efficacy. Public Health. 1990;104(1):21-5. http://dx.doi.org/10.1016/S0033-3506(05)80341-5
31. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal vaccine. Vaccine. 2011;29(49):9127-31. http://dx.doi.org/10.1016/j.vaccine.2011.09.112
32. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine. 2012;30(27):4067-72. http://dx.doi.org/10.1016/j.vaccine.2012.04.017
33. Tocheva AS, Jefferies JMC, Rubery H, Bennett J, Afimeke G, Garland J et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine. 2011;29(26):4400-4. http://dx.doi.org/10.1016/j.vaccine.2011.04.004
34. Rolo D, Fenoll A, Ardanuy C, Calatayud L, Cubero M, de la Campa AG et al. Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage. J Antimicrob Chemother. 2011;66(8):1712-8. http://dx.doi.org/10.1093/jac/dkr193
35. Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on the routine pneumococcal vaccination programme for adults aged 65 years and older. London: JCVI; 20 July 2011. [Accessed September 2014]. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/ab/JCVI/DH_094744
36. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II- a cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol. 2004;19:365-75. http://dx.doi.org/10.1023/B:EJEP.0000024752.48929.bd
37. Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Dis. 2007;23:531-40. http://dx.doi.org/10.1007/s10096-007-0327-z
38. Smith KJ, Zimmerman RK, Lin Ch J, Nowalk MP, Ko F, McEllistrem MC et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis. Vaccine. 2008;26(11):1420-31. http://dx.doi.org/10.1016/j.vaccine.2008.01.007
39. Hak E, Grobbee DE, Sanders EAM, Verheij TJM, Bolkenbaas M, Huijts SM et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-83.
40. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61(21):394-5.
41. Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on discontinuation of the routine pneumococcal vaccination programme for adults aged 65 years and older. London: JCVI; 16 March 2011. [Accessed September 2014]. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/ dh_125122.pdf